TriangleObinutuzumab (NCT07711483)
Obinutuzumab trial for Lymphoma (NCT07711483). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with qualifying large B-cell lymphoma after one treatment line, with refractory disease, relapse within twelve months, or transplant ineligibility. They must qualify for liso-cel CAR-T therapy.
The idea: give glofitamab, which links T cells to lymphoma cells, with gemcitabine and oxaliplatin while preparing liso-cel from the patient’s immune cells. Obinutuzumab precedes cell collection; lymphodepleting chemotherapy precedes liso-cel infusion. Prior CAR-T or CD20/CD3 bispecific therapy is excluded.
This phase 2 study plans 56 patients. Jeremy Abramson leads at Massachusetts General Hospital in Boston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.